Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double blind, placebo controlled phase 3 trial of immunotherapy with autologous antigen presenting cells loading with PA2024 (Provenge, APC8015) in men with metastatic androgen independent prostatic adenocarcinoma

Next Previous
X
Search
Trial Profile

A randomized, double blind, placebo controlled phase 3 trial of immunotherapy with autologous antigen presenting cells loading with PA2024 (Provenge, APC8015) in men with metastatic androgen independent prostatic adenocarcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sipuleucel-T (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPACT
  • Sponsors Dendreon Corporation

    • Most Recent Events

    • 15 Feb 2020 Interim Results assessing comparison of sipuleucel-T (sip-T) product parameters from two phase III studies IMPACT and ProVent, presented at the 2020 Genitourinary Cancers Symposium
    • 13 Feb 2020 Results published in the Dendreon Corporation media release
    • 13 Feb 2020 According to a Dendreon Corporation media release, comparison in product parameters in 2 studies(ProVent and IMPACT) were presented at the 2020 ASCO GU Cancers Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top